Aragon Pharmaceuticals raises $22M through Series B financing Aragon Pharmaceuticals Inc.

We value the chance to support the company’s efforts to develop best-in-class anti-endocrine therapies for the treatment of hormone-refractory cancers. The financing will support the business’s plans to initiate Phase 1 clinical trials in the middle of this year for its lead compound, ARN-509 for the treatment of castration-resistant prostate cancer, and allow it to keep into Phase 2 trials. The Column Group values and invests in ‘big ideas’ like Aragon‘s approach to developing treatments that circumvent the issues of drug level of resistance in hormone-delicate cancers, stated Peter Svennilson, founder and managing partner of The Column Group and chairman of Aragon. We are excited with the company’s progress to day and very supportive as Aragon techniques ARN-509 into the clinic and proceeds to build its drug discovery pipeline.We have been thrilled that Ruijin Medical center selected the Aurora Program because of their breast center. We have been worked up about the potential that China gives, also to have our initial set up come at the best teaching hospital, Ruijin Medical center, makes us incredibly optimistic about what the near future keeps for Aurora in the Chinese marketplace. Aurora has continuing to get acceptance and authorization from leading medical communities world-wide and now in another of the world’s most significant markets, stated Olivia Ho Cheng, president and ceo of Aurora Imaging Technology Inc.